NIH lutein study
This article was originally published in The Tan Sheet
Executive Summary
The second Age-Related Eye Disease Study (AREDS II) is slated to begin in Spring 2006, according to its sponsor, the National Eye Institute. The Phase III clinical trial will investigate whether oral supplementation with lutein (10 mg/day) and zeaxanthin (2 mg/day) and/or lutein and zeaxanthin in combination with omega-3 fatty acids (1 g/day) will slow the progression of age-related macular degeneration (AMD) when compared to placebo. Participants will be at moderate to high risk of AMD. The supplements' effect on cataract surgery also will be examined. To date, more than $4 mil. in funding has been awarded. The study builds off the first AREDS, which found that high-dose combination of antioxidants and zinc can lower the risk of developing advanced AMD in high-risk patients (1"The Tan Sheet" Oct. 15, 2001, p. 3)...